88768-40-5

Basic information

• Product Name: Cilazapril
• Synonyms: CILASTATIN NA;CILASTATIN SODIUM SALT;sodium hydrogen 7-[(2-amino-2-carboxylatoethyl)thio]-2-[[(2,2-dimethylcyclopropyl)carbonyl]amino]hept-2-enoate;6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, 9-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-, (1S,9S)-;6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, 9-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-, [1S-[1α,9α(R*)]]-;Ro 31-2848;Yipingshu;(1S,9S)-9-[(S)-1-Ethoxycarbonyl-3-phenylpropylamino]-10-oxoperhydropyridazino[1,2-a][1,2]diazepine-1-carboxylic acid
• CAS NO: 88768-40-5
• Molecular Formula: C₂₂H₃₁N₃O₅
• Molecular Weight: 417.5
• EINECS: 279-694-4
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;API
• Mol File: 88768-40-5.mol
• Article Data: 4

Chemical Properties

• Melting Point: 95-97°C
• Boiling Point: 598.1 °C at 760 mmHg
• Flash Point: 315.5 °C
• Appearance: Off-White Solid
• Density: 1.26 g/cm³
• Vapor Pressure: 3.73E-15mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Ethanol (Slightly, Sonicated), Methanol (Slightly)
• CAS DataBase Reference: Cilazapril(CAS DataBase Reference)
• NIST Chemistry Reference: Cilazapril(88768-40-5)
• EPA Substance Registry System: Cilazapril(88768-40-5)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• RTECS: MJ9650200
• Hazardous Substances Data: 88768-40-5(Hazardous Substances Data)

Usage

Description

Cilazapril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor cilazaprilat. In vivo, cilazapril (0.1 mg/kg) inhibits plasma ACE activity and inhibits the angiotensin I-induced pressor response in anesthetized rats and cats. It decreases systolic blood pressure in spontaneously hypertensive rats when administered at a dose of 30 mg/kg. Cilazapril (10 mg/kg, p.o.) decreases blood pressure in volume-depleted renal hypertensive dogs. Formulations containing cilazapril have been used in the treatment of hypertension.

Chemical Properties

Off-White Solid

Uses

Different sources of media describe the Uses of 88768-40-5 differently. You can refer to the following data:
1. An ACE inhibitor. Hydrolyzed in vivo to the active diacid metabolite (Cilazaprilat). Antihypertensive
2. An ACE inhibitor. Hydrolyzed in vivo to the active diacid metabolite (Cilazaprilat). Antihypertensive.

Brand name

Inhibace (Hoffmann-LaRoche).

InChI:InChI=1/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1

Upstream product

• 106860-19-9 (1S,9S)-t-butyl 9-<(1S)-ethoxycarbonyl-3-phenylpropylamino>octahydro-10-oxo-6H-pyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 29678-81-7 (R)-2-hydroxy4-phenylbutanoic acid 
• 90315-82-5 ethyl (R)-2-hydroxy-4-phenylbutyrate 
• 106928-72-7 (1S,9S)-t-butyl 1,2,3,4,7,8,9,10-octahydro-6,10-dioxo-9-phthalimidopyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 106860-13-3 (S)-2-[(S)-4-Benzyloxycarbonyl-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyryl]-tetrahydro-pyridazine-1,3-dicarboxylic acid 1-benzyl ester 3-tert-butyl ester 
• 88767-18-4 (S,S)-5-(6-(tert-butoxycarbonyl)tetrahydropyridazin-1(2H)-yl)-4-(1,3-dioxoisoindolin-2-yl)-5-oxopentanoic acid 
• 88767-16-2 (S)-4-Chlorocarbonyl-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyric acid benzyl ester 
• 106860-20-2 9-amino-octahydro-10-oxo-6H-pyridazo[1,2-a][1,2]diazepine-1-(S)carboxylic acid t-butyl ester 
• 88767-98-0 ethyl (R)-4-phenyl-2-<<(trifluoromethyl)sulfonyl>oxy>butyrate 
• 88784-33-2 (2S)-4-benzyloxicarbonyl-2-phthalimidobutanoic acid 
• 106927-97-3 (1S,9S)-t-butyl octahydro-10-oxo-9-phthalimido-6H-pyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 72064-51-8 (3S)-N¹-benzyloxycarbonyl-piperazic acid tert-butyl ester 

Downstream Products

• 90139-06-3 cilazaprilat 
• 64-17-5 ethanol 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF CILAZAPRIL

The present invention relates to a process for the preparation of optically pure (S,S)-6-t-butoxycarbonyl-hexahydro-1-pyridazinylcarbonyl-1,3-dioxo-2-isoindolebutyric acid, an intermediate for the preparation of cilazapril.

ENANTIOMERICALLY PURE CILAZAPRIL,PROCESS FOR PREPARATION

The invention relates to enantiomerically pure cilazapril and a process for preparing enantiomerically pure cilazapril. The invention also relates to pharmaceutical compositions that include the enantiomerically pure cilazapril and use of said composition